programas cribado cancer

Nota bibliográfica cribado c mama 2013-06

Wübker A. Explaining variations in breast cancer screening across European countries. The European Journal of Health Economics 2013 06/07:1-18. DOI:10.1007/s10198-013-0490-3. Enlace:

Jagsi R, Hayman J. Informing Patient Decisions Regarding Management of Ductal Carcinoma In Situ. (editorial). Journal of the National Cancer Institute 2013 June 05;105(11):758-759. DOI:10.1093/jnci/djt113.

Soeteman DI, Stout NK, Ozanne EM, Greenberg C, Hassett MJ, Schrag D, et al. Modeling the Effectiveness of Initial Management Strategies for Ductal Carcinoma In Situ. Journal of the National Cancer Institute 2013 June 05;105(11):774-781. DOI:10.1093/jnci/djt096.

Conclusions Overall survival benefits of the six management strategies for DCIS are within 1 year, suggesting that treatment decisions can be informed by the patient’s preference for breast preservation and disutility for recurrence. Our delineation of personalized outcomes for each strategy can help patients understand the implications of their treatment choice, so their decisions may reflect their own personal values and help improve the quality of care for patients with DCIS.

Marmot MG. Sorting through the arguments on breast screening. JAMA 2013 May 30:1-2. DOI:10.1001/jama.2013.6822.
To those coming fresh to the argument, such disagreement seems surprising. Given the large body of evidence evaluating breast screening, it seems that the evidence would settle the issue. Such naiveté does not allow for the fact that people interpret evidence and, indeed, influence its generation. Judgments often reflect more about starting assumptions than they do about the nature of the evidence.

Puig-Vives M, Sanchez MJ, Sanchez-Cantalejo J, Torrella-Ramos A, Martos C, Ardanaz E, et al. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study. Gynecol Oncol 2013 Jun 5 DOI:10.1016/j.ygyno.2013.05.039; PMID:23747837.
 CONCLUSION: The prognostic value of molecular subtype persists when adjusting for age, stage and histological grade. Hormone receptor positive tumors were associated with a better prognosis when compared with HER2-overexpressed and triple negative subtypes. Further research is required to improve triple negative prognosis.

Harris AL. Breast screening remains a controversial issue. (editorial). Br J Cancer 2013 Jun 11;108(11):2197. DOI:10.1038/bjc.2013.259; 10.1038/bjc.2013.259. PMID:23744282.

Hall P, Easton D. Breast cancer screening: time to target women at risk. (editorial). Br J Cancer 2013 Jun 11;108(11):2202-2204. DOI:10.1038/bjc.2013.257; 10.1038/bjc.2013.257. PMID:23744280.

Wu YY, Yen MF, Yu CP, Chen HH. Individually tailored screening of breast cancer with genes, tumour phenotypes, clinical attributes, and conventional risk factors. Br J Cancer 2013 May 14 DOI:10.1038/bjc.2013.202; 10.1038/bjc.2013.202. PMID:23674086.

Conclusion:We developed a novel quantitative approach following the principle of translational research to provide a roadmap with state-of-the-art genomic discovery and clinical parameters to facilitate individually tailored breast cancer screening.
Ceugnart L, Séradour B, Taieb S, Barreau B. Que penser des polémiques récentes sur le dépistage organisé des cancers du sein? Oncologie 2013 06/14:1-3. DOI:10.1007/s10269-013-2297-3. Enlace:

Otten JDM, Fracheboud J, den Heeten GJ, Otto SJ, Holland R, de Koning HJ, et al. Likelihood of early detection of breast cancer in relation to false-positive risk in life-time mammographic screening: population-based cohort study. Annals of Oncology 2013 June 19 DOI:10.1093/annonc/mdt227. PMID:23788759.

Conclusion Dutch women about to participate in the screening programme can be reassured that the chance of false-positive recall in the Netherlands is relatively low. A new screening policy and improved mammography have increased the detection of an early screening carcinoma and lowering the risk of interval carcinoma.
web desarrollada y mantenida por :